Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Systematic Review

Meta-analysis on the effect of combining Lianhua Qingwen with Western medicine to treat coronavirus disease 2019

Deng-chao Wang, Miao Yu, Wen-xian Xie, Li-yan Huang, Jian Wei, Yue-hua Lei

Department of General Surgery, Zigong Fourth People’s Hospital, Zigong 643000, Sichuan Province, China
Department of Basic Medicine, Sichuan Vocational College of Health and Rehabilitation, Zigong 643000, Sichuan Province, China
Department of Pathology, West China Second Hospital of Sichuan University, Chengdu 610000, Sichuan Province, China

Article history:
Received 9 September 2020
Accepted 14 September 2021
Available online 2 November 2021

Keywords:
Lianhua Qingwen
Western medicine
Coronavirus disease 2019
Meta-analysis

ABSTRACT

Background: Coronavirus disease 2019 (COVID-19) has become a worldwide life-threatening pandemic. Lianhua Qingwen is believed to possess the ability to treat or significantly improve the symptoms of COVID-19. These claims make it important to systematically evaluate the effects of using Lianhua Qingwen with Western medicine to treat COVID-19.

Objective: To evaluate the safety and efficacy of combination therapy, employing Lianhua Qingwen with Western medicine, to treat COVID-19, using a meta-analysis approach.

Search strategy: China National Knowledge Infrastructure, Wanfang Database, VIP Database, PubMed, Embase, and Cochrane Library databases were searched for studies evaluating the effect of Lianhua Qingwen-Western medicine combination therapy in the treatment of COVID-19.

Inclusion criteria: (1) Research object: hospitalized patients meeting the diagnostic criteria of COVID-19 were included. (2) Intervention measures: patients in the treatment group received Lianhua Qingwen treatment combined with Western medicine, while the control group received either Western medicine or Chinese medicine treatment. (3) Research type: randomized controlled trials and retrospective study were included.

Data extraction and analysis: Two researchers extracted the first author, the proportion of males and females, age, body temperature, course of treatment, rate of disappearance of main symptoms, duration of fever, adverse reactions, and total effectiveness from the literature. Odds ratio (OR) and 95% confidence interval (CI) were used as the effect value for count data, and mean difference (MD) and 95% CI were used as the effect value for measurement data.

Results: Six articles met the inclusion criteria, including a total of 856 COVID-19 patients. The meta-analysis showed that Lianhua Qingwen combination therapy achieved higher rates of fever reduction (OR = 3.43, 95% CI [1.78, 6.59], P = 0.0002), cough reduction (OR = 3.39, 95% CI [1.85, 6.23], P = 0.0001), recovery from shortness of breath (OR = 10.62, 95% CI [3.71, 30.40], P < 0.0001) and recovery from fatigue (OR = 2.82, 95% CI [1.44, 5.53], P = 0.003), higher total effectiveness rate (OR = 2.51, 95% CI [1.73, 3.64], P < 0.0001), and shorter time to recovery from fever (MD = –1.00, 95% CI [–1.04, 0.96], P < 0.0001), and did not increase the adverse reaction rate (OR = 0.65, 95% CI [0.42, 1.01], P = 0.06), compared to the single medication control.

Conclusion: The Lianhua Qingwen and Western medicine combination therapy is highly effective for COVID-19 patients and has good clinical safety. As only a small number of studies and patients were included in this review, more high-quality, multicenter, large-sample-size, randomized, double-blind, controlled trials are still needed for verification.

Please cite this article as: Wang DC, Yu M, Xie WX, Huang LY, Wei J, Lei YH. Meta-analysis on the effect of combining Lianhua Qingwen with Western medicine to treat coronavirus disease 2019. J Integr Med. 2022; 20(1): 26–33.
© 2022 Shanghai Yueyang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. Published by Elsevier B.V. All rights reserved.
1. Introduction

Coronavirus disease 2019 (COVID-19), characterized by acute respiratory tract symptoms, is caused by a novel coronavirus, “2019-nCoV,” and has become a global pandemic [1,2]. Common symptoms of the disease include fever, shortness of breath, fatigue, and cough; however, severely and critically ill patients can experience life-threatening respiratory failure and renal failure [3]. Conventional Western medicine, taken in conjunction with traditional Chinese medicine, has played a significant role in the resolution of these symptoms [4–6]. Lianhua Qingwen is believed to be able to treat COVID-19 and to improve its symptoms, including cough, fever, and fatigue [7]. The underlying mechanism may be a combination of broad-spectrum antibacterial, antiviral, and antipyretic activities that contribute to relieving cough, reducing phlegm, and regulating immunity [8–11]. In this study, a systematic approach was used to search for clinical trials and to evaluate the efficacy of Lianhua Qingwen taken in combination with Western medicine treatment. (3) Research type: randomized controlled trial (RCT) and retrospective study. (4) Outcome indicators: the disappearance rate of main symptoms, duration of fever, adverse reactions, and total effectiveness rate were recorded.

2. Materials and methods

2.1. Inclusion and exclusion criteria

2.1.1. Inclusion criteria

(1) Research objects: hospitalized patients meeting the diagnostic criteria of “Diagnosis and treatment of COVID-19” [12] were included. (2) Intervention measures: patients in the intervention group received a combination of Lianhua Qingwen and Western medicine treatment, while control group received either Western or Chinese medicine treatment. (3) Research type: randomized controlled trial (RCT) and retrospective study. (4) Outcome indicators: the disappearance rate of main symptoms, duration of fever, adverse reactions, and total effectiveness rate were recorded.

2.1.2. Exclusion criteria

Studies returned in the search were excluded from this meta-analysis if they were duplicates of other literature, case reports, or reviews; if they had had incomplete or unavailable outcome indicators; if they had no control group; and if their study population excluded critically ill patients.

2.2. Search strategy

The databases for the literature search included China National Knowledge Infrastructure, Wanfang Database, VIP Database, PubMed, Embase, and Cochrane Library. The search-window was from December 1, 2019, to July 14, 2020. The keywords for the search were coronavirus disease 2019, novel coronavirus-infected pneumonia, COVID-19, 2019-nCoV, and Lianhua Qingwen. The search query was formulated as follows (taking PubMed as an example, refer to the MeSH medical keywords): coronavirus disease 2019 OR novel coronavirus-infected pneumonia OR COVID-19 OR 2019-nCoV AND Lianhua Qingwen. The reference sections of returned literature were used to expand the search to studies that were not captured by the search query.

2.3. Data extraction

Two researchers strictly followed the inclusion and exclusion criteria to independently screen the literature. When there were
disagreements, a third party participated in the discussion and decided whether or not to include the study. After first screening the title and abstract for suitability, the full text of the literature was obtained and read. Data were then extracted from the papers, including the first author, the proportion of males and females, age, body temperature, course of treatment, and outcome indicators. The main indicators included the rate of reduction in primary symptoms, duration of fever, adverse reactions, and total effectiveness rate.

2.4. Literature quality assessment

Quality evaluation was performed on all the included literature. The Jadad scoring criteria were used to evaluate the quality of the randomized controlled studies [13]. The scoring criteria included random sequence generation, allocation concealment, blind methodology, and follow-up. Low-quality research literature was rated from 1–3 points; high-quality research literature was rated from 4–7 points. The Newcastle-Ottawa Scale (NOS) [14] was used to evaluate the quality of the retrospective studies. The specific scoring standards were as follows: selection, comparability, and exposure. According to the above criteria, scores > 6 points were considered high quality, and scores < 6 points were considered low quality. The evaluation process was carried out independently by two reviewers, and a third party mediated the discussion and helped reach consensus when scores were inconsistent.

2.5. Bias risk assessment

Risk assessment was conducted to evaluate the quality of the RCTs according to the Cochrane Collaboration 5.1.0 risk of bias assessment tool, including the generation of random sequence, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other biases. Each of these items was scored as high risk, low risk, and unclear risk. The evaluation process was carried out independently by two reviewers, and a third party mediated the discussion and helped reach consensus when scores were inconsistent.

2.6. Statistical methods

RevMan 5.3, provided by the Cochrane Collaboration, was used for data analysis. Odds ratio (OR) and 95% confidence interval (CI) were used as the effect measure for count data, and mean difference (MD) and 95% CI were used as the effect measure for measurement data. If there was no significant difference shown by the Q test ($P > 0.10$, $I^2 \leq 50\%$), a fixed effects model was used for analysis. If there was a significant difference ($P < 0.10$ and $I^2 > 50\%$), a random effects model was used. $P < 0.05$ was used as the threshold for significance.

3. Results

3.1. Literature search results

Initially, a total of 71 studies were retrieved from the databases, and one was manually retrieved. By reading the titles and abstracts, it was determined that 25 were duplicate studies, 13 were irrelevant to the research purpose, 23 were reviews, and 3 were case studies; these were all excluded. The remaining eight articles were re-screened after reading the full text; one study without a control group and one study with basic research were excluded. After the above step-by-step screening, 6 studies [15–20] were finally included. The screening process is illustrated in Fig. 1. The data extracted from the included studies are shown in Table 1. All the results are summarized in Table 2.

3.2. Literature quality evaluation

The two RCTs [16,20] had a Jadad score of 4 and 6, respectively, while the 4 retrospective studies [15,17–19] each had a NOS score of 7. These were all high-quality studies and were comparable at baseline.

3.3. Assessment of risk of bias

Two studies [16,20] were RCTs. Both [16,20] explained their method of randomization; one study [16] described the concealment of allocation and blinding methods, and the other [20] did not. The data from the two studies [16,20] were complete, and the selective reporting of research results and other sources of bias were not mentioned. The bias risk assessment is shown in Fig. 2 and the risk of bias summary in Fig. 3.

3.4. Meta-analysis results

3.4.1. Time to recovery from fever

Four studies [15–17,19] compared the time to recovery from fever between the combination therapy group and the single medication group. There was no statistical heterogeneity between the studies ($P = 0.78$, $I^2 = 0\%$), and a fixed effects model was used to combine the effect sizes for analysis. The combination therapy group had significantly shorter time to recovery from fever in the treatment of COVID-19 than the single medication group ($MD = -1.00$, 95% CI $[-1.04, 0.96]$, $P < 0.00001$; Fig. 4).

3.4.2. Rate of recovery from fever

Three studies [15,18,19] compared the rate of recovery from fever between the combination therapy group and the control. The average rates of recovery from fever in the combination therapy group and the control group were 85.5% (106/124) and 62.5% (60/96), respectively. No statistical heterogeneity was observed among the included studies ($P = 0.92$, $I^2 = 0\%$), and a fixed effects model was used to combine the effect sizes for analysis. We found that the combination therapy group had a significantly higher rate of recovery from fever than the control group in the treatment of COVID-19 ($OR = 3.43$, 95% CI [1.78, 6.59], $P = 0.0002$; Fig. 5).

3.4.3. Rate of recovery from cough

Three studies [15,18,19] compared the rate of recovery from cough between the combination therapy group and the control group. The rates of recovery from cough of the combination therapy group and the control group were 56.6% (60/106) and 27.9% (28/98), respectively. No statistical heterogeneity was observed among the studies ($P = 0.39$, $I^2 = 0\%$), and a fixed effects model was used to combine the effect sizes for analysis. We found that the combination therapy group had a significantly higher rate of recovery from cough than the single medication group in the treatment of COVID-19 ($OR = 3.39$, 95% CI [1.85, 6.23], $P < 0.0001$; Fig. 6).

3.4.4. Recovery from shortness of breath

Three studies [15,18,19] compared the recovery rate of shortness of breath between the combination therapy group and the single medication group. The rates of recovery from shortness of breath in the combination therapy group and the single medication group were 68.2% (30/44) and 15.4% (6/39), respectively. No statistical heterogeneity was observed among the studies ($P = 0.75$, $I^2 = 0\%$), and a fixed effects model was used to combine the effect sizes for analysis. We found that the combination therapy group had a significantly higher rate of recovery from shortness of breath.
than the single medication group in the treatment of COVID-19 (OR = 10.62, 95% CI [3.71, 30.40], \( P < 0.0001 \); Fig. 7).

3.4.5. Rate of recovery from fatigue

Three included studies [15,18,19] compared the rate of recovery from fatigue between the combination therapy group and the control group. The rates of recovery from fatigue in the combination group and the control group were 68.7% (57/83) and 42.8% (33/77), respectively. There was no statistical heterogeneity among the studies (\( P = 0.76, I^2 = 0\% \)), and a fixed effects model was used to combine the effect sizes for analysis. We found that the combination therapy group had a significantly higher rate of recovery from fatigue than the single medication group in the treatment of COVID-19 (OR = 2.82, 95% CI [1.44, 5.53], \( P = 0.003 \); Fig. 8).

3.4.6. Incidence of adverse reactions

Three included studies [16,18,20] compared adverse reactions to the treatment between the combination therapy group and

| Study         | Group     | Sample size (M/F) | Age (year) | Body temperature (°C) | Course of treatment (d) | Type of treatment | Score (Jadad/NOS) |
|---------------|-----------|-------------------|------------|-----------------------|------------------------|------------------|------------------|
| Chen et al. [15] | Experimental | 26/25             | 55.5 ± 12.3 | 38.44 ± 0.63          | 7                      | L + W            | 7                |
|               | Control   | 27/24             | 55.8 ± 11.6 | 38.33 ± 0.64          | 7                      | W                |                  |
| Hu et al. [16]  | Experimental | 79/63             | 50.4 ± 15.2 | 37.1 ± 0.7            | 14                     | L + W            | 6                |
|               | Control   | 71/71             | 51.8 ± 14.8 | 37.090 ± 0.668        | 14                     | W                |                  |
| Liu et al. [17]  | Experimental | 11/7              | 44.06 ± 14.23 | NA         | NA                    | L + W            | 7                |
|               | Control   | 6/8               | 49.85 ± 17.10 | NA        | NA                    | L                |                  |
| Lv et al. [18]   | Experimental | 28/35             | 59.12 ± 16.56 | 38.08 ± 0.63         | 10                     | L + W            | 7                |
|               | Control   | 18/20             | 60.20 ± 17.01 | 38.03 ± 0.67         | 10                     | W                |                  |
| Yao et al. [19]  | Experimental | 16/5              | 57.1 ± 14.0 | 38.56 ± 0.68          | NA                     | L + W            | 7                |
|               | Control   | 12/9              | 62.4 ± 12.3 | 38.38 ± 0.63          | NA                     | W                |                  |
| Yu et al. [20]   | Experimental | 82/65             | 48.27 ± 9.56 | 37.86 ± 0.65          | 7                      | L + W            | 4                |
|               | Control   | 89/59             | 47.25 ± 8.67 | 37.74 ± 0.57          | 7                      | W                |                  |

F: female; L: Lianhua Qingwen capsules; M: male; NA: not available; NOS: Newcastle-Ottawa Scale; RCT: randomized controlled trial; W: Western medicine.
the control group. The incidences of adverse reactions in the combination therapy group and the control group were 21.3% (68/319) and 26.6% (85/320), respectively. No statistical heterogeneity could be seen between the studies ($P = 0.27, I^2 = 17\%$), and a fixed effects model was used to combine the effect sizes for analysis. We found that there was no significant difference in the incidence of adverse reactions between the combination therapy group and the single medication group in the treatment of COVID-19 (OR = 0.65, 95% CI [0.42, 1.01], $P = 0.06$; Fig. 9).

### 3.4.7. Total effectiveness rate
Four studies [15,16,18,20] compared the total effectiveness rate between the combination therapy group and the control group. The total effectiveness rates of the combination therapy group and the control group were 85.4% (316/370) and 70.6% (262/371), respectively. No statistical heterogeneity was seen between the different studies ($P = 0.87, I^2 = 0\%$), and a fixed effects model was used to combine the effect sizes for analysis. We found that the combination therapy group had a significantly higher total effectiveness rate in the treatment of COVID-19 than the control group (OR = 2.51, 95% CI [1.73, 3.64], $P < 0.00001$; Fig. 10).

### 4. Discussion

The global COVID-19 pandemic has become increasingly severe, and it has been listed by the World Health Organization as a “public health emergency of international concern” [21,22]. COVID-19 can be classified as an “epidemic” in Chinese medicine [23]. Lianhua Qingwen capsules contain a traditional Chinese medicine preparation. It is composed of 13 Chinese medicine extracts, namely, forsythia, honeysuckle, ephedra, wood fern, Isatis root, gypsum, menthol, patchouli, rhodiola, fishwort, rhubarb, sauteed bitter almonds, and licorice [24]. It clears toxins and plays a role in regulating lung function. The drug is widely used in modern applications to treat respiratory diseases caused by viral infections [25]. Pharmacological studies have shown that Lianhua Qingwen has inhibitory effects against the severe acute respiratory syndrome virus cultured in vitro [26], provides multistage resistance to influenza A viruses H1N1 and H3N2 [27] and inhibits avian influenza virus H7N9 [28]. Lianhua Qingwen inhibits the release

---

**Table 2**

Summary of results from the meta-analysis of clinical outcomes.

| Outcome                              | Number of trials | Number of patients | L + W | C  | $P$ value | $I^2$ | OR or MD | 95% CI       | $P$ value for heterogeneity |
|--------------------------------------|------------------|--------------------|-------|----|-----------|-------|----------|--------------|-----------------------------|
| Time to recovery from fever          | 4                | 419                | 217   | 202| 0.78      | –1.00 | –1.04, 0.96| < 0.00001    |                             |
| Fever recovery rate                  | 3                | 220                | 124   | 96 | 0.92      | 3.43  | 1.78, 6.59| < 0.0002     |                             |
| Cough recovery rate                  | 3                | 209                | 106   | 93 | 0.39      | 3.39  | 1.85, 6.23| < 0.0001     |                             |
| Shortness of breath recovery rate    | 3                | 83                 | 44    | 39 | 0.75      | 10.62 | 3.71, 30.40| < 0.0001     |                             |
| Fatigue recovery rate                | 3                | 160                | 83    | 77 | 0.76      | 2.82  | 1.44, 5.33| 0.003        |                             |
| Adverse reaction rate                | 3                | 639                | 319   | 320| 0.27      | 4.37  | 0.42, 1.01| 0.06         |                             |
| Total effectiveness rate             | 4                | 741                | 370   | 371| 0.87      | 2.51  | 1.73, 3.64| < 0.00001    |                             |

C: control group; CI: confidence interval; L: Lianhua Qingwen capsules; MD: mean difference; OR: odds ratio; W: Western medicine.
### Table 1: Comparison of the time to recovery from fever between the two groups.

| Study or subgroup | Experimental | Control | Mean difference | IV, Fixed, 95% CI |
|-------------------|--------------|---------|-----------------|-------------------|
|                   | Mean (SD)    | Mean (SD) | Mean difference |                   |
| Chen et al. (2020)| 2.9 (1.7)    | 3.9 (1.3) | 0.3%            | -1.00 [-1.75, -0.25] |
| Hu et al. (2020) | 2 (0.17)     | 3.0 (0.17) | 100.6%          | -1.00 [-1.04, -0.96] |
| Liu et al. (2020) | 4.28 (1.97)  | 5.79 (1.15) | 14%             | -1.51 [-2.80, -0.42] |
| Yao et al. (2020) | 4.6 (3.2)    | 6.1 (3.1)  | 21%             | -1.50 [-3.41, 0.41] |
| Total (95% CI)   | 217          | 202      | 100.0%          | -1.00 [-1.04, -0.96] |

Heterogeneity: $Chi^2 = 1.10, df = 3 (P = 0.78); I^2 = 0%$

Test for overall effect: $Z = 49.72 (P < 0.00001)$

---

### Figure 4. Comparison of the time to recovery from fever between the two groups.

---

### Table 2: Comparison of the rate of recovery from fever between the two groups.

| Study or subgroup | Experimental | Control | Odds ratio | M-H, Fixed, 95% CI |
|-------------------|--------------|---------|------------|-------------------|
|                   | Events (Total) | Events (Total) | Total (95%) CI |                   |
| Chen et al. (2020)| 36 (43)      | 25      | 42.5%      | 3.29 [1.18, 9.17] |
| Lv et al. (2020) | 52 (60)      | 23      | 40.0%      | 3.11 [1.10, 8.75] |
| Yao et al. (2020)| 18 (21)      | 12      | 17.5%      | 4.50 [1.01, 20.11] |
| Total (95% CI)   | 124          | 96      | 100.0%     | 3.43 [1.78, 6.59] |

Total events: 210

Heterogeneity: $Chi^2 = 0.17, df = 2 (P = 0.92); I^2 = 0%$

Test for overall effect: $Z = 3.70 (P = 0.0002)$

---

### Figure 5. Comparison of the rate of recovery from fever between the two groups.

---

### Table 3: Comparison of the rate of recovery from cough between the two groups.

| Study or subgroup | Experimental | Control | Odds ratio | M-H, Fixed, 95% CI |
|-------------------|--------------|---------|------------|-------------------|
|                   | Events (Total) | Events (Total) | Total (95%) CI |                   |
| Chen et al. (2020)| 23 (37)      | 14      | 39%        | 2.93 [1.15, 7.45] |
| Lv et al. (2020) | 30 (54)      | 11      | 36%        | 2.84 [1.17, 6.91] |
| Yao et al. (2020)| 7 (15)       | 1       | 18%        | 4.26 [1.56, 14.20] |
| Total (95% CI)   | 106          | 93      | 100.0%     | 3.39 [1.85, 6.23] |

Total events: 206

Heterogeneity: $Chi^2 = 1.89, df = 2 (P = 0.39); I^2 = 0%$

Test for overall effect: $Z = 3.93 (P < 0.0001)$

---

### Figure 6. Comparison of the rate of recovery from cough between the two groups.

---

### Table 4: Comparison of the rate of recovery from shortness of breath between the two groups.

| Study or subgroup | Experimental | Control | Odds ratio | M-H, Fixed, 95% CI |
|-------------------|--------------|---------|------------|-------------------|
|                   | Events (Total) | Events (Total) | Total (95%) CI |                   |
| Chen et al. (2020)| 8 (13)       | 2       | 14%        | 3.53 [1.48, 6.26] |
| Lv et al. (2020) | 15 (22)      | 4       | 20%        | 5.90 [2.08, 15.32] |
| Yao et al. (2020)| 7 (9)        | 0       | 7.0%       | 33.00 [1.31, 833.87] |
| Total (95% CI)   | 44           | 39      | 100.0%     | 10.62 [3.71, 30.40] |

Total events: 70

Heterogeneity: $Chi^2 = 0.57, df = 2 (P = 0.75); I^2 = 0%$

Test for overall effect: $Z = 4.41 (P < 0.0001)$

---

### Figure 7. Comparison of the rate of recovery from shortness of breath between the two groups.

---

### Table 5: Comparison of the rate of recovery from fatigue between the two groups.

| Study or subgroup | Experimental | Control | Odds ratio | M-H, Fixed, 95% CI |
|-------------------|--------------|---------|------------|-------------------|
|                   | Events (Total) | Events (Total) | Total (95%) CI |                   |
| Chen et al. (2020)| 19 (31)      | 12      | 35%        | 3.03 [1.11, 8.29] |
| Lv et al. (2020) | 33 (40)      | 17      | 29%        | 3.32 [1.11, 10.00] |
| Yao et al. (2020)| 5 (12)       | 4       | 13%        | 1.81 [0.31, 8.32] |
| Total (95% CI)   | 83           | 77      | 100.0%     | 2.82 [1.44, 5.53] |

Total events: 160

Heterogeneity: $Chi^2 = 0.56, df = 2 (P = 0.76); I^2 = 0%$

Test for overall effect: $Z = 3.01 (P = 0.003)$

---

### Figure 8. Comparison of the rate of recovery from fatigue between the two groups.
of inflammatory mediators in the body, thereby ameliorating the damage to lung tissue [29]. It has antibacterial effect against secondary bacterial infections after viral infections, reduces fever, and has anti-inflammatory properties [30–32], thereby promoting the relief of symptoms related to COVID-19. The latest network pharmacology research shows that Lianhua Qingwen can show its efficacy against coronavirus via multiple pathways, targets, and components. The active ingredients display a binding affinity to main protease and angiotensin-converting enzyme 2, and the mechanism encompasses a broad-spectrum antibacterial, antiviral and antipyretic effects, amelioration of phlegm and cough, immune regulation, suppression of virus-induced nuclear factor-κB activation and reduction in the expression of interleukin-6 (IL-6), IL-8, tumor necrosis factor-α, and interferon-inducible protein-10 genes [33,34].

In the present meta-analysis, 6 studies meeting the inclusion criteria were included. In total, there were 442 cases in the combination therapy group and 414 cases in the control (single medication) group. Five studies used Lianhua Qingwen in the form of granules, and one study used a capsule; 4 studies reported the course of treatment, and two studies did not report the course of treatment. The results showed that, the total effectiveness rate of combination therapy was greater than that of the single medication control (OR = 2.51, 95% CI [1.73, 3.64], \( P < 0.00001 \)). The main symptoms (fever, cough, shortness of breath, and fatigue) was improved, and the time to recovery from fever was shortened (MD = −1.00, 95% CI [−1.04, 0.96], \( P < 0.00001 \)). Thus, a combination of Lianhua Qingwen and Western medicine has positive clinical outcomes against COVID-19. This meta-analysis also compared the rates of adverse reactions between the combination therapy and the single medication treatment in the management of COVID-19, and the difference was not statistically significant (OR = 0.65, 95% CI [0.42, 1.01], \( P = 0.06 \)). This suggests that the granular form of Lianhua Qingwen is safe for clinical application. However, in clinical treatment, it is still necessary to pay attention to the adverse reactions. Most of the adverse reactions to Lianhua Qingwen capsules occurred after the first use and involved the gastrointestinal system and skin, mainly manifesting as nausea, vomiting, abdominal distension, diarrhea, rash, or itching. In clinical practice, attention should be paid to the dosage and course of treatment, and adverse reactions should be closely monitored [35].

This study has several shortcomings. First, the number of included studies was small, and the studies were all conducted in China, so it is difficult to conduct subgroup analysis of other regions and races. Second, most of the studies were non-randomized double-blind studies, and high-quality, multicenter, large-sample-size, randomized, double-blind, controlled trials are still needed to verify the results. Third, some of the included studies did not report all of the important details, such as: there was no mention of blinding in the randomized study, and in two studies, the course of treatment was unknown.

5. Conclusion

This meta-analysis confirmed that Lianhua Qingwen, taken in combination with Western medicine can significantly improve the main symptoms of patients with COVID-19; this treatment approach is able to shorten the time to recovery from fever, has significant clinical efficacy and causes few adverse reactions. Combination therapy with Lianhua Qingwen and Western medicine was effective in patients with mild to moderate COVID-19. However, due to the few studies available, the present analysis had a small sample size, and multicenter, large-sample-size RCTs are still needed to verify the therapeutic advantages of including Chinese medicine in treatment of COVID-19.

Funding

No funding was received for this study.

Author contributions

DCW and MY designed this study, and WXX executed the search strategy; JW and YHL collected the data, and DCW and MY re-checked the data; JW and YHL performed the analysis, and
DCW re-checked the analysis; JW and YHL assessed the quality of the studies, and DCW and MY re-checked the quality of the studies; DCW wrote the manuscript, and JW edited the manuscript. All listed authors reviewed and revised the manuscript. DCW and MY contributed equally to this work.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak—an update on the status. Mil Med Res 2020;7(1):11.
[2] Tobyas M, Qashqary M, Al Dahery N, Mjallad A, Hershon AA, Kamal MA, et al. Therapeutic management of COVID-19 patients: a systematic review. Infect Prev Pract 2020;2(3):100061.
[3] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497–506.
[4] Liu M, Gao Y, Yuan Y, Yang K, Shi S, Zhang J, et al. Efficacy and safety of integrated traditional Chinese and Western medicine for corona virus disease 2019 (COVID-19): a systematic review and meta-analysis. Pharmacol Res 2020;158:104896.
[5] Chen LL, Ge GB, Rong Y, Fu W, Zheng MY, Zhao YF, et al. Application and research progress of Chinese medicine in the prevention and treatment of new coronavirus pneumonia. Shanghai Zhong Yi Yao Da Xue Xue Bao 2020;34(3):1–8 [Chinese with abstract in English].
[6] Yang Y, Islam MS, Wang J, Li Y, Chen X. Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective. Int J Biol Sci 2020;16(10):1708–17.
[7] Wang YZ, Liu F, Zhang XL. Application of oral Chinese patent medicine for coronavirus disease-19. Zhongguo Yi Yuan Yang Yao Ping Jia Yu Fen Xi 2020;20(3):257–67 [Chinese with abstract in English].
[8] Yang C, Wang Y, He J, Tan W, Jiang H, Chen Q, et al. Lianhua-Qingwen displays antiviral and anti-inflammatory activity and synergistic effects with oseltamivir against influenza B virus infection in the mouse model. Evid Based Complement Altern Med 2020;2020:3196375.
[9] Zhang D, Zhang B, Lv JT, Sa RN, Zhang XM, Liu JZ. The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence. Pharmacol Res 2020;157:104882.
[10] Wang L, Yang ZH, Zhang HR, Yu HK, Yang K, Fu BH, et al. Study on the network pharmacology and preliminary evidence of Lianhua Qingwen in the treatment of novel coronavirus (2019-nCoV). Zhong Yao Cai 2020;43(3):772–8 [Chinese with abstract in English].
[11] Ding Q, Lu P, Fan Y, Xu Y, Liu M. The clinical characteristics of pneumonia patients infected with 2019 novel coronavirus and influenza virus in Wuhan, China. J Med Virol 2020;92(9):1549–55.
[12] General Office of National Health Commission of the People's Republic of China, Office of National Administration of Traditional Chinese Medicine Diagnosis and treatment of coronavirus disease-2019 5 (7th trial edition). Zhongguo Yi Yao 2020;15(6):801–5 [Chinese].
[13] Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17(1):1–12.
[14] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25(9):603–5.
[15] Cheng D, Wang W, Li Y. Analysis of cumulative effect of 51 patients with novel coronavirus pneumonia treated with Chinese medicine Lianhua Qingwen: a multicentre retrospective study. Tianjin Zhong Yi Yao 2020;37(5):509–16 [Chinese with abstract in English].
[16] Hu K, Guan WJ, Bi Y, Zhang W, Li L, Zhang B, et al. Efficacy and safety of Lianhuaqinqwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial. Phytomedicine 2021;85:153242.
[17] Liu LL, Yuan LF, Feng Y, Sun D, Liu WS, Wang YJ, et al. Clinical study on combined scheme of Lianhuaqinqwen capsules and abidol in the treatment for coronavirus disease. Guangdong Yi Xue 2020;41(12):1207–10 [Chinese with abstract in English].
[18] Lv RB, Wang WJ, Li X. Clinical observation on Lianhua Qingwen Granules combined with Western medicine conventional therapy in the treatment of G3 suspected cases of coronavirus disease 2019. Zhong Yi Za Zhi 2020;61(8):655–9 [Chinese with abstract in English].
[19] Yao KT, Liu MY, Li X, Huang JH, Cai HB. Retrospective clinical analysis on treatment of coronavirus disease 2019 with traditional Chinese medicine Lianhua Qingwen. Zhongguo Shi Yan Fang Ji Xue Za Zhi 2020;26(11):8–12 [Chinese with abstract in English].
[20] Yu P, Li YZ, Yan SB, Wang Y. The efficacy of Lianhua Qingwen Granules combined with abidol in the treatment of mild novel coronavirus pneumonia. Zhongguo Yao Xue Za Zhi 2020;55(12):1042–5 [Chinese with abstract in English].
[21] Abd El-Aziz TM, Stockand JD. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2)—an update on the status. Infect Genet Evol 2020;83:104327.
[22] Allam M, Cai S, Ganesh S, Venkatesan M, Doodhwalla S, Song Z, et al. COVID-19 diagnostics, tools, and prevention. Diagnostics 2020;10(6):409.
[23] Tian XL, Hua C, Zhang Y, Zhao Y. Progress in the prevention and control of COVID-19 by Lianhuaqinqwen Capsule. Liaoning Zhong Yi Yao Da Xue Xue Bao 2020;22(8):184–7 [Chinese with abstract in English].
[24] Bi D, Sun YB, Song LQ, Ren J, Zhang CF, Shen S. Study of chemical components from Lianhua Qingwen Capsule (1). Zhong Cao Yao 2018;49(4):795–800 [Chinese with abstract in English].
[25] Li HR, Chang LP, Wei C, Jia ZH. Theoretical research basis and clinical efficacy of Lianhua Qingwen in treating novel coronavirus pneumonia. Shi Jie Zhong Yi Yao 2020;15(3):332–6 [Chinese with abstract in English].
[26] Runfeng L, Yunlong H, Jicheng H, Weng P, Qinbai M, Yongxia S, et al. Lianhuaqinqwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res 2020;156:104761.
[27] Niu QQ, Chen Y, Liu Y, Mao SZ, Wang H, Zheng WK, et al. Efficacy and safety of Lianhuaqinqwen capsule for influenza: a systematic review. Zhongguo Zhong Yao Za Zhi 2020;42(6):1474–81 [Chinese with abstract in English].
[28] Mo HY, Ke CW, Zheng JP, Zhong NS. Antiviral effects of Lianhuaqinqwen capsule against influenza virus in vitro. Zhong Yao Xue Yu Yau Yu Lin Chuang Li Zhi 2007;18(1):5–9 [Chinese with abstract in English].
[29] Li Q, Yin J, Ran QS, Yang Q, Liu L, Zhao Z, et al. Efficacy and mechanism of Lianhuaqinqwen capsules (LHQW) on chemotaxis of macrophages in acute lung injury (ALI) animal model. Zhongguo Zhong Yao Za Zhi 2019;44(11):2317–23 [Chinese with abstract in English].
[30] Huang YF, Bai C, He F, Xie Y, Zhou H. Review on the potential action mechanisms of Chinese medicines in treating coronavirus disease 2019 (COVID-19). Pharmacol Res 2020;158:104939.
[31] Luo H, Yang M, Tang QL, Hu XY, Wilcock ML, Liu JP. How can traditional Chinese medicine contribute to the therapeutic approach in coronavirus disease 2019 (COVID-19)? A review of the registered clinical trials. (2020-06) [2021-06-16]. https://doi.org/10.21203/rs.3.rs-32800/v1.
[32] Gao D, Niu M, Wei SZ, Zhang CF, Zhou YF, Yang ZW, et al. Identification of a pharmacological biomarker for the bioassay-based quality control of a thirteen-component TCM formula (Lianhuaqinqwen) used in treating influenza A virus (H1N1) infection. Front Pharmacol 2020;11:746.
[33] Ding Y, Zeng L, Li R, Chen Q, Zhou B, Chen Q, et al. The Chinese prescription Lianhuaqinqwen Capsules exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function. BMC Complement Altern Med 2017;17(1):136.
[34] Ling XY, Tao JL, Sun X. Exploring material basis and mechanism of Lianhuaqingwen formula against coronavirus based on network pharmacology. Zhong Yao Cai 2020;51(7):1723–30 [Chinese with abstract in English].
[35] Peng LL, Li L, Shen J, Li XL. Literature analysis of clinical application and adverse drug reaction/event of Lianhua Qingwen capsule. Zhongguo Yao Wu Jing Jie 2016;12(12):753–5 [Chinese with abstract in English].